Protective Immunity to Dengue Virus Induced by DNA Vaccines Encoding Nonstructural Proteins in a Lethal Challenge Immunocompetent Mouse Model

Alves, Rúbens Prince dos Santos; Andreata-Santos, Robert; Freitas, Carla; Pereira, Lennon Ramos; Fabris-Maeda, Denicar Lina Nascimento; Rodrigues-Jesus, Mônica Josiane; Pereira, Samuel Santos; Carvalho, Alexia Adrianne Venceslau Brito; Sales, Natiely Silva; Peron, Jean Pierre Schatzmann; Amorim, Jaime Henrique; Ferreira, Luís Carlos de Souza

doi:10.3389/fmedt.2020.558984

Cited by 2 publications

(2 citation statements)

References 83 publications

(113 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, the protective potential of a DNA vaccine composed only of non-structural proteins from DENV2 was evaluated in a murine model ( 156 ). Three recombinant plasmids based on the pVAX-1 vector were constructed encoding NS1, NS3, and NS5 from DENV2.…”

Section: Dengue Dna Vaccinesmentioning

confidence: 99%

Dengue Virus and Vaccines: How Can DNA Immunization Contribute to This Challenge?

Alves

Costa

Pinto

2021

Front. Med. Technol.

View full text Add to dashboard Cite

Dengue infections still have a tremendous impact on public health systems in most countries in tropical and subtropical regions. The disease is systemic and dynamic with broad range of manifestations, varying from mild symptoms to severe dengue (Dengue Hemorrhagic Fever and Dengue Shock Syndrome). The only licensed tetravalent dengue vaccine, Dengvaxia, is a chimeric yellow fever virus with prM and E genes from the different dengue serotypes. However, recent results indicated that seronegative individuals became more susceptible to develop severe dengue when infected after vaccination, and now WHO recommends vaccination only to dengue seropositive people. One possibility to explain these data is the lack of robust T-cell responses and antibody-dependent enhancement of virus replication in vaccinated people. On the other hand, DNA vaccines are excellent inducers of T-cell responses in experimental animals and it can also elicit antibody production. Clinical trials with DNA vaccines have improved and shown promising results regarding the use of this approach for human vaccination. Therefore, in this paper we review preclinical and clinical tests with DNA vaccines against the dengue virus. Most of the studies are based on the E protein since this antigen is the main target for neutralizing antibody production. Yet, there are other reports with DNA vaccines based on non-structural dengue proteins with protective results, as well. Combining structural and non-structural genes may be a solution for inducing immune responses aging in different infection moments. Furthermore, DNA immunizations are also a very good approach in combining strategies for vaccines against dengue, in heterologous prime/boost regimen or even administering different vaccines at the same time, in order to induce efficient humoral and cellular immune responses.

show abstract

Section: Dengue Dna Vaccinesmentioning

confidence: 99%

Dengue Virus and Vaccines: How Can DNA Immunization Contribute to This Challenge?

Alves

Costa

Pinto

2021

Front. Med. Technol.

View full text Add to dashboard Cite

show abstract

“…TMC NPs are known to be a strong inducer of the humoral immune response [ 10 , 11 ]. In addition, T cell responses are also significant for protection against dengue virus infection [ 12 , 13 ]. Therefore, it is important to formulate a vaccine that stimulates strong and sustainably high levels of both antibody and T cell responses.…”

Section: Introductionmentioning

confidence: 99%

The Adjuvant Activity of BCG Cell Wall Cytoskeleton on a Dengue Virus-2 Subunit Vaccine

Jearanaiwitayakul,

Warit,

Lekjinda

et al. 2023

Vaccines

View full text Add to dashboard Cite

The uneven immunogenicity of the attenuated tetravalent dengue vaccine has made it difficult to achieve balanced protection against all four serotypes of the dengue virus (DENV). To overcome this problem, non-replicative vaccines have come into focus, as their immunogenicity is adjustable. This approach is excellent for multivalent vaccines but commonly faces the issue of low immunogenicity. In this present study, we developed a non-replicating dengue vaccine composed of UV-inactivated dengue virus-2 (UV-DENV-2) and DENV-2 NS1-279 protein encapsidated within nanoparticles. This vaccine candidate was administered in the presence of BCG cell wall cytoskeleton (BCG-CWS) as an adjuvant. We revealed, here, that encapsidated immunogens with BCG-CWS exerted potent activities on both B and T cells and elicited Th-1/Th-2 responses in mice. This was evidenced by BCG-CWS significantly augmenting antibody-mediated complement-fixing activity, strongly stimulating the antigen-specific polyfunctional T cell responses, and activating mixed Th-1/Th-2 responses specific to DENV-2- and NS1-279 antigens. In conclusion, BCG-CWS potently adjuvanted the inactivated DENV-2 and DENV subunit immunogens. The mechanism of adjuvanticity remains unclear. This study revealed the potential use of BCG-CWS in vaccine development.

show abstract

Protective Immunity to Dengue Virus Induced by DNA Vaccines Encoding Nonstructural Proteins in a Lethal Challenge Immunocompetent Mouse Model

Cited by 2 publications

References 83 publications

Dengue Virus and Vaccines: How Can DNA Immunization Contribute to This Challenge?

Dengue Virus and Vaccines: How Can DNA Immunization Contribute to This Challenge?

The Adjuvant Activity of BCG Cell Wall Cytoskeleton on a Dengue Virus-2 Subunit Vaccine

Contact Info

Product

Resources

About